Top

Breast Cancer Research and Treatment

Published in:

01-02-2021 | Cancer Biomarker | Clinical trial

Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population

Authors: Ziyao Li, Ying Wang, Cong Liu, Zhenzhen Wang, Dongmo Wang, Xingyu Liang, Jiawei Tian

Published in: Breast Cancer Research and Treatment | Issue 1/2021

Abstract

Purpose

To investigate the associations of four commonly studied single nucleotide polymorphisms (SNP) of the vascular endothelial growth factor (VEGF), including -460T/C (rs833061), − 634G/C (rs2010963), − 2578C/A (rs699947), and +936T/C (rs3025039), with the incidence, aggressiveness, and tumor markers expression of breast cancer in the Northern China Han population.

Methods

Followed the genomic DNA extraction, a total of 259 patients with breast cancer (case group) and 273 healthy women (control group) underwent genotyping by PCR-LDR SNP assays. The associations between VEGF gene polymorphisms and the incidence, aggressiveness, and tumor markers expression of breast cancer were analyzed.

Results

Significant differences were observed in allele frequency and genotype distribution of − 634G/C between breast cancer cases and healthy controls (p = 0.006, 0.013). Individuals who carry the G allele more likely had a lower risk of breast cancer (OR, 0.866, 95% CI 0.782–0.959). Compared with CC genotype carriers, women who had the CG and GG genotypes demonstrated a relatively lower risk (OR, 0.860, 95% CI 0.757–0.978, p = 0.022; OR, 0.778, 95% CI, 0.656–0.924, p = 0.004, respectively). When we stratified the group of patients according to the status of tumor markers, a significant association of − 634G/C SNP and Ki-67 expression was observed. The CC genotype carriers were more likely to be characterized by high expression of Ki-67 (p = 0.031). Further analysis showed that the − 460T/-634C/-2578C/+936C haplotype was more associated with a higher risk of breast cancer (OR, 1.445, 95% CI 1.123–1.859, p = 0.004), whereas the − 460T/− 634G/− 2578C/+936C one was associated with a lower risk (OR, 0.736, 95% CI 0.563–0.963, p = 0.025).

Conclusions

In the present study, we concluded that VEGF gene − 634G/C polymorphism is related to the incidence of breast cancer in the Han population in Northern China and also might be associated with tumor proliferation index Ki-67.

Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P (2014) Breast cancer statistics and markers. J Cancer Res Therapeut 10(3):506–511

Su J, Wang J, Luo J, Li H (2019) Ultrasound-mediated destruction of vascular endothelial growth factor (VEGF) targeted and paclitaxel loaded microbubbles for inhibition of human breast cancer cell MCF-7 proliferation. Mol Cell Probes 46:101415CrossRef

Liu Y, Zhang J, Huang R, Feng WL, Kong YN, Xu F, Zhao L, Song QK, Li J, Zhang BN (2017) Influence of occupation and education level on breast cancer stage at diagnosis, and treatment options in China: a nationwide, multicenter 10-year epidemiological study. Medicine 96(15):e6641CrossRef

Al Balawi IA, Mir R, Abu-Duhier FM (2018) Potential impact of vascular endothelial growth factor gene variation (-2578C>A) on breast cancer susceptibility in saudi arabia: a case-control study. Asian Pac J Cancer Prev 19(4):1135–1143PubMedPubMedCentral

Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15(6):1148–1152CrossRef

Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121–3128CrossRef

Roy H, Bhardwaj S, Ylä-Herttuala S (2006) Biology of vascular endothelial growth factors. Febs Letters 580(12):2879–2887CrossRef

Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Edler L, Lubiński J, Scott RJ, Hamann U (2008) The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 262(1):71–76CrossRef

Su JB, Kim JW, Kang H, Hwang SG, Kim NK (2008) Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea. Anticancer Research 28(2B):1271–1276

10.

Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232–1235CrossRef

11.

Wang K, Peng HL, Li LK (2012) Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis. Asian Pacific J Cancer Prevent Apjcp 13(11):5665–5669CrossRef

12.

Zhou Y, Li N, Zhuang W, Wu X (2011) Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Gastric Cancer Risk in a Chinese Han Population. Molecular Carcinogenesis 50(3):184–188CrossRef

13.

Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, Karakitsos P (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48(6):563–569CrossRef

14.

García-Closas M, Malats N, Real FX, Yeager M, Chanock SJ (2007) Large-scale evaluation of candidate genes identifies associations between VEGF Polymorphisms and bladder cancer risk. Plos Genetics 3(2):e29CrossRef

15.

Su JL, Lee SY, Jeon HS, Sun HP, Park JY (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prevent 14(3):571–575CrossRef

16.

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106(4):468–471CrossRef

17.

Jin Q (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res Off J Am Assoc Cancer Res 11(10):3647–3653CrossRef

18.

Rahoui J, Sbitti Y, Touil N, Laraqui A, Ibrahimi A, Rhrab B, Al Bouzidi A, Moussaoui Rahali D, Dehayni M, Ichou M et al (2014) The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women. Med Oncol 31(12):336CrossRef

19.

Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56(2):167–173CrossRef

20.

Sa-Nguanraksa D, O-Charoenrat P (2012) The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci 13(12):14845–14864CrossRef

21.

Madisen L, Hoar DI, Holroyd CD, Crisp M, Hodes ME, Reynolds JF (1987) The effects of storage of blood and isolated DNA on the integrity of DNA. Am J Med Genet Part A 27(2):379–390CrossRef

22.

Huang K, Tang W, Tang R, Xu Z, He Z, Li Z, Xu Y, Li X, He G, Feng G et al (2008) Positive association between OLIG2 and schizophrenia in the Chinese Han population. Hum Genet 122(6):659–660CrossRef

23.

Lelièvre L, Clézardin P, Magaud L, Roche L, Tubiana-Mathieu N, Tigaud JD, Topart D, Raban N, Mouret-Reynier MA, Mathevet P (2018) Comparative study of neoadjuvant chemotherapy with and without zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: the NEOZOL Study. Clin Breast Cancer 18(6):e1311–e1321CrossRef

24.

Kiso M, Tanaka S, Saji S, Toi M, Sato F (2018) Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Int J Cancer 143(11):2905–2918CrossRef

25.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR et al (2013) Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108(5):1052–1060CrossRef

26.

Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795–803CrossRef

27.

Morabito A, Sarmiento R, Bonginelli P, Gasparini G (2004) Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol/hematol 49(2):91–107CrossRef

28.

Salven P, Perhoniemi V, Tykkä H, Mäenpää H, Joensuu H (1999) Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 53(2):161–166CrossRef

29.

Carpini JD, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13(3):279–279CrossRef

30.

Ma J, Hu W, Zhang P, Sun Y, Wang N, Teng X, Qiao Q (2015) The association between VEGF +936C/T and -634G/C polymorphisms and breast cancer susceptibility, tumor growth, and metastases: evidence from 20,728 subjects. Cancer Invest 33(7):312–317CrossRef

31.

O-Charoenrat P (2014) Vascular endothelial growth factor polymorphisms affect gene expression and tumor aggressiveness in patients with breast cancer. Mol Med Rep 9(3):1044–1048CrossRef

32.

Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, Kummalue T, Rojananin S, Ratanawichhitrasin A, Prasarttong-Osoth P, Chuthatisith S, Pisarnturakit P, Aeumrithaicharoenchok W et al (2013) Vascular endothelial growth factor 634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol Med Rep 8(4):1242–1250CrossRef

33.

Zhang H, Sui X, Zhou S, Hu L, Huang X (2019) About Correlation of conventional ultrasound characteristics of breast tumors with axillary lymph node metastasis and ki-67 expression in patients with breast cancer. J Ultrasound Med 38(9):2523CrossRef

34.

Chung MJ, Lee JH, Kim SH, Suh YJ, Choi HJ (2016) Simple prediction model of axillary lymph node positivity after analyzing molecular and clinical factors in early breast cancer. Med (Baltimore) 95(20):e3689CrossRef

35.

Oliveira C, Lourenço GJ, Silva PMR, Cardoso-Filho C, Favarelli MHC, GonçAles NSL, Gurgel MSC, Lima CSP (2011) Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumor Biol 32(2):295–300CrossRef

36.

Luo T, Chen L, He P, Hu QC, Zheng H (2013) Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a chinese population. Asian Pacific J Cancer Prevent Apjcp 14(4):2433–2437CrossRef

37.

38.

Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M (2008) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111(1):157–163CrossRef

39.

Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8(2):R22CrossRef

40.

Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, Wascher TC, Paulweber B, Samonigg H, Krippl P (2008) Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat 109(2):297–304CrossRef

Title: Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population
Authors: Ziyao Li
Ying Wang
Cong Liu
Zhenzhen Wang
Dongmo Wang
Xingyu Liang
Jiawei Tian
Publication date: 01-02-2021
Publisher: Springer US
Keywords: Cancer Biomarker
Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 1/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-06024-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells

Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer

Letter to the editor re: Shah et al.: “The impact of monitoring techniques on progression to chronic breast cancer‑related lymphedema: a meta‑analysis comparing bioimpedance spectroscopy versus circumferential measurements”

Letter to the Editor regarding the publication titled “Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?”

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

Letter to editor re: Shah et al.: “The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements”

Keynote webinar | Spotlight on antibody–drug conjugates in cancer